Mohelnikova-Duchonova B, Melichar B, Soucek P. FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World J Gastroenterol 2014; 20(30): 10316-10330 [PMID: 25132748 DOI: 10.3748/wjg.v20.i30.10316]
Corresponding Author of This Article
Beatrice Mohelnikova-Duchonova, MD, PhD, Department of Oncology, Palacky University Medical School and Teaching Hospital, IP Pavlova 6, 77525 Olomouc, Czech Republic. d.beatrice@seznam.cz
Research Domain of This Article
Oncology
Article-Type of This Article
Topic Highlight
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Aug 14, 2014; 20(30): 10316-10330 Published online Aug 14, 2014. doi: 10.3748/wjg.v20.i30.10316
FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy
Beatrice Mohelnikova-Duchonova, Bohuslav Melichar, Pavel Soucek
Beatrice Mohelnikova-Duchonova, Pavel Soucek, Department of Toxicogenomics, National Institute of Public Health, 10042 Prague, Czech Republic
Beatrice Mohelnikova-Duchonova, Bohuslav Melichar, Department of Oncology, Palacky University Medical School and Teaching Hospital, 77525 Olomouc, Czech Republic
Author contributions: Mohelnikova-Duchonova B and Soucek P conceived the review; Mohelnikova-Duchonova B, Melichar B and Soucek P drafted the manuscript and performed its revisions.
Supported by Internal Grant Agency of the Czech Ministry of Health, No. NT14329-3; Research project Biomedreg, No. CZ.1.05/2.1.00/01.0030; Project from European Regional Development Fund, No. CZ.1.05/2.1.00/03.0076; and the project of the Palacky University, No. LF_2013_010
Correspondence to: Beatrice Mohelnikova-Duchonova, MD, PhD, Department of Oncology, Palacky University Medical School and Teaching Hospital, IP Pavlova 6, 77525 Olomouc, Czech Republic. d.beatrice@seznam.cz
Telephone: +420-775-270283
Received: October 29, 2013 Revised: March 5, 2014 Accepted: April 15, 2014 Published online: August 14, 2014
Core Tip
Core tip: 5-fluorouracil/leucovorin combined with oxaliplatin (FOLFOX) and irinotecan (FOLFIRI) represent the most effective chemotherapy regimens for colorectal carcinoma patients with distant metastases. Pharmacogenetics represents a promising strategy for the individualization of therapy, including identification of patients at increased risk of toxicity. This review summarizes contemporary knowledge about associations of gene and protein expression and genetic variability of putative biomarkers for the response of colorectal cancer to FOLFOX/FOLFIRI regimens. From the published data reviewed it is obvious that the problem is highly complex and the ultimate profile of the drug-sensitive or resistant patient will most probably be jointly defined by genetic, epigenetic, intracellular, extracellular, and extrinsic factors.
